Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program FDAThe U.S.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) FDA The U.S. RegulatoryRead full story Post navigation Previous: Ambrosia adds a megaround for obesity drugsNext: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
